Paris NASH, 2021
An Engineered Fatty Acid, Icosabutate, Targets Free-Fatty Acid Receptor 4 (GPR120) via the β-arrestin-2 Internalisation Pathway
Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: Results of an interim analysis of the Phase 2b ICONA trial.
Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis
Liver international, 2020
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
Hepatology Communications, 2019
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
EASL poster 2020: Decline in NASH- and atherosclerosis-associated oxidised phospholipids and 7-ketocholesterol in response to icosabutate therapy
EASL 2019 late-breaker poster: Icosabutate a structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH
EASL 2019 poster: Icosabutate induces a potent reduction in hepatic oxidative stress in multiple rodent models of metabolic stress and fibrosing NASH
AASLD 2018 poster: Icosabutate, a novel structurally engineered fatty-acid, exhibits potent anti-inflammatory and anti-fibrotic effects in a dietary mouse model resembling progressive human NASH
AASLD 2018 poster: A liver-targeted structurally engineered fatty acid, icosabutate, potently reduces hepatic pro-fibrotic gene expression and improves glycemic control in an obese diet-induced mouse model of NASH
EASL 2018 late-breaker poster: A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients.
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”
Voor meer informatie:
+31 (0) 35 760 65 05